MOTS-c protected kidneys from diabetes damage in mice, by helping kidney cells clear stored fat
in diabetic mice and human kidney cells in the lab
In diabetic mice and human kidney cells in the lab, the mitochondrial peptide MOTS-c cut protein leakage into the urine, cleared fat from kidney cells and slowed their aging.
What happened
A team in China tested MOTS-c on diabetic kidney disease. The paper appeared online in Biochemical Pharmacology on 23 October 2026.
They worked with db/db mice, a strain bred to develop diabetes, and with human kidney tubule cells grown in the lab. MOTS-c protected the kidneys in a dose-dependent way: the more the mice got, the better their urine albumin-to-creatinine ratio held up. That ratio measures how much protein leaks into the urine, one of the first signs that diabetes is damaging the kidneys.
Treated mice also had less damage to the kidney tubules, less fat stuck in kidney tissue and fewer immune cells moving in. Markers of cell aging went down too.
How it works
Diabetes makes kidney cells store fat they cannot burn. That fat stresses the cells and pushes them into senescence, a state where they stop working properly and leak inflammation.
Cells have a clean-up system for stored fat called lipophagy. A protein called LARS1 acts as a brake on it. In this study MOTS-c turned LARS1 down, so the clean-up ran again and the fat droplets were cleared.
The researchers checked that this was the reason. When they forced kidney cells to make extra LARS1, the protection disappeared. When they blocked the clean-up system in mice with a drug called 3-MA, most of MOTS-c's benefit disappeared too.
What it means for you
This is early science. The results come from diabetic mice and from cells in a dish, not from people, and the abstract does not give effect sizes or the doses used.
What it adds is a clear mechanism. MOTS-c is a short peptide that mitochondria make themselves, and it keeps turning up in research on metabolism and aging. This study links it to the kidney, one of the organs diabetes damages most.
What's next
Diabetic kidney disease is a leading cause of kidney failure, and the authors note that current treatments do not stop it from progressing. They point to the LARS1, fat clean-up and cell-aging pathway as a new target. Studies in people would be the next step.
The numbers
- Published online 23 October 2026 in Biochemical Pharmacology
- Tested in diabetic db/db mice and in human kidney tubule cells (HK-2) in the lab
- MOTS-c preserved the urine albumin-to-creatinine ratio in a dose-dependent way
- Less tubular injury, less fat buildup, fewer macrophages and fewer markers of cell aging
- Extra LARS1 or blocking fat clean-up with 3-MA cancelled the protection
The original: Biochemical Pharmacology (PubMed abstract)
